Filing Flows › Comparisons › INBX vs LCTX
Inhibrx Biosciences vs Lineage Cell Therapeutics: INBX and LCTX compared
Inhibrx Biosciences is the larger company: $1.3M of revenue in its latest quarter (Q2 2025) against $1.1M for Lineage Cell Therapeutics (Q2 2026). Inhibrx Biosciences is growing faster (13× against -61% a year earlier).
Where the money goes: INBX and LCTX
Inhibrx Biosciences (INBX) · Q2 2025
Inhibrx Biosciences, Q2 2025: revenue $1.3M (13× year over year), net loss $28.7M, operating cash flow −$30.0M. The chart follows the revenue to costs, profit and cash.
Lineage Cell Therapeutics (LCTX) · Q2 2026
Lineage Cell Therapeutics, Q2 2026: revenue $1.1M (-61% year over year), operating margin -834.7%, net earnings $1.5M, operating cash flow −$7.2M. The chart follows the revenue to costs, profit and cash.
| Inhibrx Biosciences (INBX) | Lineage Cell Therapeutics (LCTX) | |
|---|---|---|
| Latest quarter | Q2 2025 | Q2 2026 |
| Revenue | $1.3M | $1.1M |
| Revenue growth, Y/Y | 13× | -61% |
| Operating margin | n/m | -834.7% |
| Net earnings | −$28.7M | $1.5M |
| Net margin | — | 144.4% |
| Operating cash flow | −$30.0M | −$7.2M |
Where the revenue comes from
Lineage Cell Therapeutics
- Collaboration Revenues: $943K (88%)
- Royalties License and Other Revenues: $126K (12%)
Questions
Which is bigger, Inhibrx Biosciences or Lineage Cell Therapeutics?
Inhibrx Biosciences is the larger company: $1.3M of revenue in its latest quarter (Q2 2025) against $1.1M for Lineage Cell Therapeutics (Q2 2026).
Is Inhibrx Biosciences or Lineage Cell Therapeutics growing faster?
Inhibrx Biosciences is growing faster (13× against -61% a year earlier).
More: Inhibrx Biosciences earnings · how Inhibrx Biosciences makes money · Lineage Cell Therapeutics earnings · how Lineage Cell Therapeutics makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Aug 13, 2025; 10-Q filed Aug 6, 2026). Fiscal quarters can end on different dates. Not investment advice.